Free Newsletter
King Pharma to lay off 20 percent
Free newsletter via e-mail
Tools
It's not just Big Pharma that's restructuring. King Pharmaceuticals plans to lay off 20 percent of its workforce and embark on a cost-cutting regime. The prompt: Possible loss of patent coverage on its Altace remedy for heart failure and high blood pressure. A U.S. Court of Appeals recently ruled against the company, but King has asked the judges to reconsider.
- check out King's release
Related Articles:
King cuts 20 percent of workforce. Report
King regroups after patent fight loss. Report
King bails on Palatin's FSM program. Report
FDA rejects King's Altace. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: